JAK inhibitors and adverse cardiovascular events: Class effect or molecule-specific risk? (PubMed, Front Pharmacol) - Sep 24, 2026 - "Randomized trials, observational studies, and pharmacovigilance analyses involving tofacitinib, baricitinib, upadacitinib, and filgotinib have produced heterogeneous findings, with no consistent replication of a uniform class-wide cardiovascular signal. Mechanistic plausibility exists for both hypotheses through shared JAK-STAT pathway effects on vascular inflammation and thrombosis. This narrative review synthesizes current evidence from clinical trials, real-world data, and regulatory perspectives to critically assess the available evidence regarding whether cardiovascular risk represents a class effect or a molecule-specific phenomenon."
Adverse events • Journal • Review • Cardiovascular • Hematological Disorders • Immunology • Inflammatory Arthritis • Myocardial Infarction • Oncology • Rheumatoid Arthritis • Rheumatology • Thrombosis
|